A Trial Evaluating Two Subcutaneous Injection Techniques and Intramuscular Administration of Degarelix in Patients With Prostate Cancer

Inclusion Criteria: * Aged ≥18 years with a diagnosis of adenocarcinoma of the prostate (Gleason graded, all stages) where endocrine treatment is indicated. * Caucasian origin. * Able to provide written Informed Consent and willing and able to comply with trial procedures. * Body mass index (BMI) between 18.5-30 kg/m2. * Has a life expectancy of at least one year. Exclusion Criteria: * Current hormonal management of prostate cancer. * Previous endocrine therapy for prostate cancer within 3 months prior to the screening visit. * Any medical injection therapy that might interfere with degarelix injections. * Patients with advanced muscle atrophy or cachexia which in the Investigator's opinion would preclude or pose risks of complications following ventrogluteal i.m. injection of degarelix. * Any medical condition that could be aggravated or may cause extreme discomfort during the trial period or could cause a moderate risk to a patient (significant heart, renal or liver disease). * Chronic pain syndrome or any continuous pain reported by the patient that, according to the judgement of the Investigator, could limit the evaluation of injection related pain.